Compare ArcelorMittal SA (MT) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Nuvalent Inc — how do they compare? ArcelorMittal SA trades at $66.25 (market cap $50.01B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: ArcelorMittal SA is far larger — about 5.1× Nuvalent Inc's market cap, and ArcelorMittal SA pays a 0.91% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MT | NUVL | |
|---|---|---|
Market Cap | $50.01B | $9.81B |
Sector | Basic Materials | Technology |
52-Week High | $71.65 | $123.96 |
52-Week Low | $30.39 | $72.16 |
Enterprise Value | $59.33B | $8.52B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $65.80, down 0.98% today, with a bullish technical outlook supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.24 and P/S of 0.81. Recent corporate developments include ongoing share buybacks and a strategic AI collaboration with AWS to enhance operational efficiency.
The outlook for MT is cautiously optimistic, driven by earnings strength and cost initiatives, but faces risks from cyclical steel demand and high capital expenditures. Analyst sentiment is mixed with 50% buy ratings, suggesting potential upside if operational improvements continue, though investors should monitor global economic conditions impacting steel prices.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
